#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Congenital nephrogenic diabetes insipidus Richter's syndrome Thalassaemia beta Chronic graft versus host disease Autoimmune haemolytic anaemia SAPHO syndrome Bile acid synthesis disorder Metastases to peritoneum Spinal cord injury cervical Neurodegenerative disorder Hyperinsulinaemic hypoglycaemia Waldenstrom's macroglobulinaemia refractory Indolent systemic mastocytosis Thyroid cancer metastatic More trials…

    Learn about Rare Diseases

    Langerhans’ cell histiocytosis Gastrointestinal stromal tumour – Treatment Marginal zone lymphoma refractory – Diagnostics Mucopolysaccharidosis I – Diagnostics Indolent systemic mastocytosis – Trials in Disease Hereditary optic atrophy – Basic Information Pleural mesothelioma malignant – Life with Disease Mantle cell lymphoma stage III – Basic Information Castleman’s disease – Basic Information Mucopolysaccharidosis II – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Omp12 Clofutriben Nitrofurantoin Rp1 Norfloxacin SKB410 AZD6234 Izorlisib Mesilate Gefurulimab Regn9933 Mk-1942 Permethrin Alnus Glutinosa Pollen Fluorouracil Anhydrous Docetaxel Festuca Elatior Pollen Extract Gadobenate Dimeglumine Aripiprazole Macrogol 4000 Flutemetamol (18F) More therapies…

    Learn about Your Condition

    Ependymoma malignant Coeliac disease H1N1 influenza Congenital aplastic anaemia Neonatal anoxia Clinically isolated syndrome Ischaemic skin ulcer Epidermolysis bullosa Cervix carcinoma Angiosarcoma Delirium Craniosynostosis Spermatocele Systemic mastocytosis Amyloidosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Klinikum Nuernberg

Klinikum Nuernberg

Breslauer Strasse 201, Langwasser, Nürnberg, 90471, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Tranexamic Acid to Reduce Bleeding and Transfusion Needs in Patients Undergoing Major Abdominal Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Procedural haemorrhage
    Investigated Drugs:
    • Tranexamic Acid
    • Sodium Chloride
    Germany

  • Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma recurrent
    Investigated Drugs:
    • Montelukast Sodium
    • Pomalidomide
    • Dexamethasone
    Czechia France Germany Greece Hungary Italy +4

  • Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine Hydrochloride
    • Nivolumab
    Austria Belgium Finland France Germany Greece +5

  • Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cetrelimab
    • Cisplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Greece +4

  • Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Pulmonary embolism
    Investigated Drugs:
    • Alteplase
    Austria France Germany Italy The Netherlands Poland +2

  • Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Non-small cell lung cancer stage IV
    • Non-small cell lung cancer
    Investigated Drugs:
    • Osimertinib
    Germany

  • Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Capivasertib
    • Abiraterone Acetate
    Belgium Bulgaria Czechia France Germany The Netherlands +3

  • Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Fludarabine Phosphate Ph. Eur.
    • Idecabtagene Vicleucel
    • Cyclophosphamide Monohydrate
    Austria Belgium Czechia Denmark France Germany +6

  • Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Pembrolizumab
    Belgium France Germany Italy Poland Spain

  • Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Diphenhydramine
    • Forimtamig
    • Carfilzomib
    Denmark France Germany Italy Spain
Previous Page
1 … 7 8 9 10 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!